Report Phase 2 results for povorcitinib in vitiligo and prurigo nodularis
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Feb 2023
- Due
- 31 Dec 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“two Phase 2 trials in vitiligo and prurigo nodularis are ongoing, with results expected in 2023.”
What we found
Evidence strength A What the grades mean
Filings show Phase 2 povorcitinib results were presented for vitiligo and announced for prurigo nodularis in October 2023, before the 2023 deadline.
-
A Incyte 10-K filed 2024-02-13
“In October 2023, positive 52-week data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib in adult patients with extensive nonsegmental vitiligo were presented at EADV as a late-breaking oral presentation.” ✓ confirmed on the page
-
A Incyte 10-K filed 2025-02-10
“In October 2023, we announced that the Phase 2, randomized, double-blind, placebo-controlled, dose ranging study evaluating the efficacy and safety of povorcitinib in participants with PN had met its primary endpoint.” ✓ confirmed on the page
Market reaction: the shares moved +1.8% against the S&P 500 over the three sessions around the disclosure (12 Feb 2024 to 15 Feb 2024). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Povorcitinib Phase 2 vitiligo and prurigo nodularis results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Incyte? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-INCY-005707 · Corrections policy